Preliminary Safety and Efficacy of Navitoclax Plus Ruxolitinib in Janus Kinase Inhibitor-Naïve Patients With Myelofibrosis From the Multicenter, Open-Label, Phase 2 Study (REFINE) - PubMed
3 hours ago
- #clinical trial
- #BCL-2 inhibitor
- #myelofibrosis
- Study evaluates navitoclax plus ruxolitinib in JAKi-naïve myelofibrosis patients.
- Primary endpoint: 63% achieved ≥35% spleen volume reduction (SVR35) at week 24.
- Secondary outcomes: 41% achieved ≥50% symptom score reduction (TSS50); 48% showed bone marrow fibrosis improvement.
- Anemia response rates: 38% in transfusion-independent, 100% in transfusion-dependent patients.
- Safety profile was tolerable with no navitoclax-attributed bleeding or deaths.